Stock value rise of Mauna Kea Technologies thanks to the Juncker Plan

The European Investment Bank (EIB) has granted a loan of €22.5 million to Manua Kea Technologies under the European Strategic Investment Fund (EFSI) or Juncker Plan.

Mauna Kea Technologies is a global medical device company aiming at eliminating uncertainties in diagnosis and treatment through direct tissue visualisation at the cellular level, called “optical biopsy”. This loan will enable Mauna Kea Technologies to develop its commercial activities, invest in its research, development and innovation activities and increase its production capacity, in line with the strong evolution of demand over the coming years.

The first €11.5 million are expected to be released in the coming weeks, while the subsequent tranches of €6 million and €5 million will be released later, subject to the achievement of certain objectives, including the Company’s commercial progress and future equity financing activities.

After ten minutes of quotation, Mauna Kea Technologies jumped 14.66% to 2.19 euros on the Paris stock exchange.

In June 2019, the Juncker plan mobilised nearly 410 billion euros of additional investment across the EU, including 69.3 billion in France. The plan currently supports 952,000 SMEs in Europe.